Charles Schwab Investment Management Inc. Buys 156,675 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)

Charles Schwab Investment Management Inc. boosted its position in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 202.1% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 234,191 shares of the company's stock after purchasing an additional 156,675 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.45% of Janux Therapeutics worth $10,639,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Summit Securities Group LLC bought a new stake in shares of Janux Therapeutics in the second quarter valued at about $29,000. Amalgamated Bank raised its stake in Janux Therapeutics by 61.1% in the 2nd quarter. Amalgamated Bank now owns 970 shares of the company's stock worth $41,000 after purchasing an additional 368 shares in the last quarter. Plato Investment Management Ltd bought a new stake in Janux Therapeutics in the 2nd quarter valued at about $42,000. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Janux Therapeutics by 21.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company's stock worth $87,000 after purchasing an additional 339 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Janux Therapeutics during the 2nd quarter worth approximately $151,000. 75.39% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on JANX shares. Leerink Partnrs upgraded Janux Therapeutics to a "strong-buy" rating in a research note on Friday, November 22nd. UBS Group started coverage on Janux Therapeutics in a report on Thursday, October 24th. They set a "buy" rating and a $69.00 target price on the stock. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $100.00 price target on shares of Janux Therapeutics in a research note on Thursday, November 7th. William Blair reaffirmed an "outperform" rating on shares of Janux Therapeutics in a research report on Tuesday, December 3rd. Finally, BTIG Research lifted their price objective on shares of Janux Therapeutics from $82.00 to $100.00 and gave the company a "buy" rating in a research note on Tuesday, December 3rd. One analyst has rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Janux Therapeutics has a consensus rating of "Buy" and a consensus price target of $79.90.

Janux Therapeutics Stock Up 0.3 %

Shares of NASDAQ JANX traded up $0.19 during midday trading on Tuesday, reaching $61.84. 657,609 shares of the company were exchanged, compared to its average volume of 781,710. The stock's 50-day moving average price is $51.30 and its 200-day moving average price is $46.36. The stock has a market cap of $3.25 billion, a P/E ratio of -56.04 and a beta of 3.30. Janux Therapeutics, Inc. has a one year low of $7.79 and a one year high of $71.71.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.51) earnings per share for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.18). Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. The firm had revenue of $0.44 million for the quarter, compared to the consensus estimate of $1.50 million. The business's quarterly revenue was down 82.6% on a year-over-year basis. On average, equities research analysts anticipate that Janux Therapeutics, Inc. will post -1.35 EPS for the current year.

Insider Transactions at Janux Therapeutics

In related news, major shareholder Ventures Xi L.P. Avalon sold 158,031 shares of Janux Therapeutics stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $47.00, for a total transaction of $7,427,457.00. Following the sale, the insider now directly owns 2,959,175 shares in the company, valued at $139,081,225. This trade represents a 5.07 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO David Alan Campbell sold 15,000 shares of the business's stock in a transaction that occurred on Tuesday, December 3rd. The stock was sold at an average price of $67.00, for a total transaction of $1,005,000.00. Following the sale, the chief executive officer now directly owns 242,054 shares in the company, valued at $16,217,618. The trade was a 5.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 350,063 shares of company stock worth $16,939,972. Insiders own 29.40% of the company's stock.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.